Related Experiment Video
Updated: Sep 23, 2026
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Enteral immunotherapy in the treatment of chronic enterocolitis in interleukin-10-deficient mice
Olivier Glehen1, François Mithieux, Alexandra Traverse-Glehen
1Surgical Department, Centre Hospitalo-Universitaire Lyon-Sud, Laboratoire Hyperthermie-Oncologie EA 643, Université Lyon 1, France.
Background/Aims:
Transgenic IL-10-deficient mice (IL-10 ko mice) spontaneously develop a chronic inflammatory bowel disease that is reminiscent of Crohn's disease. In a randomized, prospective, comparative study, we evaluated the effect of local, endoluminal immunotherapy by duodenal injection of mouse recombinant IL-10 (rm IL-10), in IL-10 ko mice with chronic enterocolitis; the first of its kind.
Methodology:
Sixteen IL-10 ko mice received a monoinjection of rm IL-10 into the duodenum while a control group of 16 IL-10 ko mice received an injection of physiological saline. Histology of the entire bowel and plasma concentrations of IL-4, IL-6, IL-10, tumor necrosis factor-alpha, and interferon-gamma were analyzed on the 3rd or 7th postoperative day.
Results:
The histological features of the specimens from IL-10 ko mice were, non-specific, segmentary and located mainly in the ileum. Lesions were of more significance in mice injected with physiological saline than in those receiving IL-10 in the proximal ileum, near to the site of injection. Plasma concentrations of IL-6 were higher in IL-10 ko mice than in the control group.
Conclusions:
This study confirms that there is hyperproduction of Th1 cytokines in IL-10 ko mice and also suggests that endoluminal administration of IL-10 may be envisaged for the treatment or prevention of enterocolitis.
